Company Description

Ilonov is a preclinical stage biotech developing first-in-class biotherapies against diabetes, harvesting the breakthrough potential of the muscle secretome to regulate metabolism, a novel and unexplored approach. Our strategy is based on a high-risk high-reward approach aiming first at developing a functional cure by potentiating pancreatic islet transplant and next generation beta cell replacement therapies to treat Type 1 Diabetes. Follow on indications include T2D & metabolic diseases.